What Is Tesamorelin?
Tesamorelin is a synthetic analogue of endogenous human growth hormone-releasing hormone (GHRH), consisting of the full 44-amino acid GHRH sequence with a trans-3-hexenoic acid group attached at the N-terminus. This modification substantially increases plasma stability compared to native GHRH by conferring resistance to dipeptidyl peptidase IV (DPP-IV) cleavage โ the primary degradation pathway for unmodified GHRH in circulation.
Unlike exogenous growth hormone administration, Tesamorelin acts upstream at the pituitary, stimulating the somatotroph cells to release GH in a pulsatile, physiological pattern. This distinction is central to its research profile and differentiates it mechanistically from direct GH secretagogues such as GHRPs or MK-677.
Mechanism of Action
Tesamorelin's mechanism is well-defined relative to many research peptides, owing to its close structural relationship with endogenous GHRH:
GHRH Receptor Binding
Tesamorelin binds selectively to the GHRH receptor (GHRHR) on pituitary somatotroph cells. This interaction activates adenylyl cyclase via Gs protein coupling, elevating intracellular cAMP and triggering downstream GH synthesis and secretion. The result is augmented GH pulse amplitude while preserving the natural pulsatile release pattern โ a finding that distinguishes it from continuous GH infusion models.
IGF-1 Axis Modulation
Increased pituitary GH output downstream elevates hepatic insulin-like growth factor-1 (IGF-1) production. IGF-1 is a key mediator of GH's anabolic and lipolytic effects in peripheral tissues. Preclinical and clinical research consistently documents IGF-1 elevation following Tesamorelin administration, making IGF-1 a practical downstream biomarker for assessing GH axis response in research settings.
Lipolytic Activity
GH exerts direct lipolytic effects on adipose tissue via hormone-sensitive lipase activation. Tesamorelin-stimulated GH release has been extensively studied in the context of visceral adiposity, with research focusing on the GH/IGF-1 axis as a regulator of fat distribution โ particularly visceral versus subcutaneous depots.
Key Research Findings
| Research Area | Model | Key Observation |
|---|---|---|
| Visceral Fat Reduction | Human (HIV-associated lipodystrophy) | Significant reduction in trunk fat area vs. placebo at 26 weeks |
| IGF-1 Elevation | Human / Rat | Consistent dose-dependent IGF-1 increases documented across multiple studies |
| GH Pulse Amplitude | Human | Augmented GH mean pulse amplitude while preserving pulsatile pattern |
| Cognitive Function | Human (mild cognitive impairment) | Improvements in executive function and verbal memory observed in 20-week trial |
| Cardiovascular Markers | Human | Improvements in triglycerides and carotid IMT thickness reported in lipodystrophy cohorts |
| Glucose Metabolism | Human | Modest, transient increases in fasting glucose โ an area of active investigation |
Tesamorelin has one of the more robust clinical data sets among GHRH analogues, largely due to its development as a pharmaceutical compound (approved as Egrifta in 2010 for HIV-associated lipodystrophy). This background provides a substantial body of controlled human research that is relatively rare in the peptide research space. All findings referenced here pertain to research contexts.
Tesamorelin vs. Other GH Secretagogues
Understanding how Tesamorelin differs from structurally or functionally related compounds helps contextualize its research profile:
| Compound | Class | Primary Target | GH Release Pattern |
|---|---|---|---|
| Tesamorelin | GHRH Analogue | GHRHR (pituitary) | Pulsatile (physiological) |
| CJC-1295 | GHRH Analogue (DAC) | GHRHR (pituitary) | Sustained / blunted pulsatility |
| Sermorelin | GHRH Fragment (1โ29) | GHRHR (pituitary) | Pulsatile (shorter half-life) |
| Ipamorelin | GHRP / Ghrelin Mimetic | GHSR-1a | Pulsatile, selective |
| MK-677 | GHS / Ghrelin Mimetic | GHSR-1a (oral) | Sustained, non-pulsatile elevation |
Purity Standards
Reconstitution Protocol
- Allow vial to reach room temperature before opening
- Swab the vial stopper and BAC water vial with alcohol
- Draw the calculated volume of bacteriostatic water
- Inject BAC water slowly along the vial wall โ do not inject directly onto powder
- Gently swirl until fully dissolved โ solution should be clear and colorless
- Label with date and concentration, refrigerate immediately
| Vial Size | BAC Water | Concentration |
|---|---|---|
| 10 mg | 1 mL | 10,000 mcg/mL |
| 10 mg | 2 mL | 5,000 mcg/mL |
| 10 mg | 5 mL | 2,000 mcg/mL |
Storage Guidelines
| Form | Storage | Shelf Life |
|---|---|---|
| Lyophilized (unopened) | โ20ยฐC freezer | 24+ months |
| Lyophilized (opened) | โ20ยฐC freezer | 12 months |
| Reconstituted | 2โ8ยฐC refrigerator | 30 days |
Frequently Asked Questions
How does Tesamorelin differ from direct GH administration?
Tesamorelin acts upstream at the pituitary GHRH receptor, stimulating the body's own GH secretion in a pulsatile pattern. Direct GH administration bypasses this axis entirely. The pulsatile pattern produced by Tesamorelin more closely mirrors endogenous GH physiology, which is a key distinction in research studying the GH/IGF-1 axis.
What purity should I look for in Tesamorelin?
Research-grade Tesamorelin should show โฅ99% HPLC purity confirmed by an independent third-party lab. Due to its 44-amino acid length, sequence verification via mass spectrometry is particularly important. Evo Peptides provides COA documentation for every batch โ available at evopeptidesus.com/coas.
Is Tesamorelin stable after reconstitution?
Reconstituted Tesamorelin should be stored at 2โ8ยฐC and used within 30 days. As with all peptides of this chain length, avoid freeze-thaw cycles after reconstitution and protect from light. Lyophilized powder is considerably more stable and should be stored at โ20ยฐC.
For research use only. Not for human or animal use. Visit evopeptidesus.com to order.